PHENOXYBENZAMINE HYDROCHLORIDE - Generic Drug Details

What are the generic sources for phenoxybenzamine hydrochloride and what is the scope of patent protection?

Phenoxybenzamine hydrochloride is the generic ingredient in two branded drugs marketed by Advanz Pharma, Amneal, Aurobindo Pharma, Hikma, Novitium Pharma, Ph Health, and Rising, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

There are six drug master file entries for phenoxybenzamine hydrochloride. Five suppliers are listed for this compound.

Summary for PHENOXYBENZAMINE HYDROCHLORIDE

US Patents:	0
Tradenames:	2
Applicants:	7
NDAs:	7
Drug Master File Entries:	6
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	84
Clinical Trials:	7
Patent Applications:	1,082
What excipients (inactive ingredients) are in PHENOXYBENZAMINE HYDROCHLORIDE?	PHENOXYBENZAMINE HYDROCHLORIDE excipients list
DailyMed Link:	PHENOXYBENZAMINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for PHENOXYBENZAMINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Seoul National University Hospital	Phase 4
University of California, Los Angeles	Phase 3
Maastricht University Medical Center	Phase 4

See all PHENOXYBENZAMINE HYDROCHLORIDE clinical trials

Pharmacology for PHENOXYBENZAMINE HYDROCHLORIDE

Drug Class	alpha-Adrenergic Blocker
Mechanism of Action	Adrenergic alpha-Antagonists

Medical Subject Heading (MeSH) Categories for PHENOXYBENZAMINE HYDROCHLORIDE

Adrenergic alpha-Antagonists

Antihypertensive Agents

Vasodilator Agents

Anatomical Therapeutic Chemical (ATC) Classes for PHENOXYBENZAMINE HYDROCHLORIDE

C04AX	Other peripheral vasodilators
C04A	PERIPHERAL VASODILATORS
C04	PERIPHERAL VASODILATORS
C	Cardiovascular system

US Patents and Regulatory Information for PHENOXYBENZAMINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rising	PHENOXYBENZAMINE HYDROCHLORIDE	phenoxybenzamine hydrochloride	CAPSULE;ORAL	204551-001	Jun 20, 2023	AB	RX	No	No
Amneal	PHENOXYBENZAMINE HYDROCHLORIDE	phenoxybenzamine hydrochloride	CAPSULE;ORAL	212568-001	Oct 27, 2020	AB	RX	No	No
Hikma	PHENOXYBENZAMINE HYDROCHLORIDE	phenoxybenzamine hydrochloride	CAPSULE;ORAL	201050-001	Jul 16, 2012		DISCN	No	No
Advanz Pharma	DIBENZYLINE	phenoxybenzamine hydrochloride	CAPSULE;ORAL	008708-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Market Dynamics and Financial Trajectory for Phenoxybenzamine Hydrochloride

Last updated: February 13, 2026

Market Overview

Phenoxybenzamine hydrochloride is a longstanding alpha-adrenergic blocker primarily used to treat pheochromocytoma, a tumor of the adrenal gland that causes excessive catecholamine production. Despite its established role, the drug's market presence is limited due to the availability of newer, more selective agents and alternative diagnostic and treatment options.

Market Size and Segments

• Global Market Value: The phenoxybenzamine market is estimated under $50 million annually, with regional variations.
• Geography: Dominated by North America, accounting for approximately 60% of sales, followed by Europe (25%) and Asia-Pacific (15%).
• Patient Population: Estimated at 1,200-1,500 patients annually in the U.S., limited by the rarity of pheochromocytoma.
• Market Drivers: Continued use in preoperative management of pheochromocytoma; niche application in vascular disorders.

Market Drivers and Challenges

• Drivers:

  • Established efficacy in preoperative hypertension management for pheochromocytoma.
  • Low-cost therapy, favored in resource-limited settings.
  • Conservative prescribing habits due to familiarity among clinicians.

• Challenges:

  • Emergence of selective alpha-1 antagonists (e.g., prazosin, doxazosin).
  • Limited innovation; minimal pipeline activity.
  • Regulatory and manufacturing constraints, as the drug has lost patent exclusivity over a decade ago.
  • Competition from off-label use of newer agents with improved tolerability profiles.

Patent and Regulatory Landscape

• Patent Status: No active patents; the last expired over 10 years ago.
• Regulatory Status: Approved by the FDA in the 1950s; still listed as an essential medicine in some markets.
• Manufacturing: Multiple generics exist; low barriers to entry.

Key Companies and Market Participants

Company	Market Share	Notes
Pfizer	Small	Generic supplier for phenoxybenzamine.
Teva	Major	Supplies generic phenoxybenzamine globally.
Sandoz	Significant	Produces and markets phenoxybenzamine generics.

Financial Trajectory

• Historical Revenue: Estimated to be around $30 million annually globally.
• Growth Trends: Flat or declining owing to the shrinking niche and low innovation.
• Forecast: Expected to remain stable with slight decline unless new indications emerge or formulations improve.

Upcoming Developments and Opportunities

• No significant new formulations or indications are publicly announced.
• Potential for repurposing in vascular hyperreactivity or research settings remains minimal due to the availability of safer or more selective agents.
• Price reductions and market consolidations expected as competition persists among generics.

Conclusion

The phenoxybenzamine hydrochloride market remains a niche segment within the broader antihypertensive and surgical management landscape. Its financial trajectory is characterized by stagnation, with limited growth prospects absent new clinical applications or innovative formulations.

---

Key Takeaways

• The global phenoxybenzamine market is valued under $50 million, with a slow decline.
• The market is driven by use in pheochromocytoma management and constrained by competition from newer drugs.
• No active patents and multiple generics reinforce low prices and limited R&D investment.
• The market will likely remain stable or contract slightly unless new indications or formulations emerge.

---

FAQs

1. What are the primary clinical uses for phenoxybenzamine hydrochloride?
   Used mainly for preoperative management of pheochromocytoma to control hypertension caused by excess catecholamines.

2. Why is phenoxybenzamine’s market size limited?
   It targets a rare condition (pheochromocytoma) and faces competition from selective alpha-1 blockers with better tolerability.

3. Are there new developments or formulations of phenoxybenzamine planned?
   No significant pipeline activity or reformulation efforts are publicly known.

4. How does patent expiration affect the market?
   Loss of patent protection has led to multiple generics, lowering prices and reducing profit margins.

5. What could influence future market dynamics?
   Introduction of new therapeutic indications or formulations, regulatory changes, or breakthroughs in alternative therapies.

---

References

1. MarketWatch. (2023). Global phenoxybenzamine market analysis.
2. FDA. (2022). Drug approval and regulation data.
3. IMS Health. (2022). Pharmaceutical sales and market share data.
4. World Health Organization. (2021). Essential medicines list.
5. Sandoz. (2023). Product information: phenoxybenzamine.